Citi Pharma Past Earnings Performance

Past criteria checks 4/6

Citi Pharma has been growing earnings at an average annual rate of 26%, while the Pharmaceuticals industry saw earnings growing at 6.3% annually. Revenues have been growing at an average rate of 16.9% per year. Citi Pharma's return on equity is 16.1%, and it has net margins of 7.3%.

Key information

26.0%

Earnings growth rate

10.9%

EPS growth rate

Pharmaceuticals Industry Growth20.2%
Revenue growth rate16.9%
Return on equity16.1%
Net Margin7.3%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Citi Pharma makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

KASE:CPHL Revenue, expenses and earnings (PKR Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 2412,9339413810
30 Jun 2412,4098333810
31 Mar 2413,0738063610
31 Dec 2312,2036873370
30 Sep 2311,9806073390
30 Jun 2312,3976583400
31 Mar 2311,0506363040
31 Dec 2211,1107332750
30 Sep 2210,9077002630
30 Jun 229,7806543700
31 Mar 229,3696503120
31 Dec 218,4015422920
30 Sep 216,5083673210
30 Jun 215,7953522010
31 Mar 215,1982962480
30 Jun 203,5281431730
30 Jun 192,607281840
30 Jun 182,0031171210

Quality Earnings: CPHL has high quality earnings.

Growing Profit Margin: CPHL's current net profit margins (7.3%) are higher than last year (5.1%).


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: CPHL's earnings have grown significantly by 26% per year over the past 5 years.

Accelerating Growth: CPHL's earnings growth over the past year (55%) exceeds its 5-year average (26% per year).

Earnings vs Industry: CPHL earnings growth over the past year (55%) did not outperform the Pharmaceuticals industry 56%.


Return on Equity

High ROE: CPHL's Return on Equity (16.1%) is considered low.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/10 18:29
End of Day Share Price 2025/01/10 00:00
Earnings2024/09/30
Annual Earnings2024/06/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Citi Pharma Limited is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Sunny KumarTopline Securities (Pvt.) Limited